# Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma

> **NCT06562621** · PHASE1,PHASE2 · COMPLETED · sponsor: **Beijing Neurosurgical Institute** · enrollment: 38 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Gliomas, Malignant

## Interventions

- **BIOLOGICAL:** ON-01
- **DRUG:** ONF

## Key facts

- **NCT ID:** NCT06562621
- **Lead sponsor:** Beijing Neurosurgical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-01
- **Primary completion:** 2022-08-01
- **Final completion:** 2024-03-01
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06562621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06562621, "Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06562621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*